The Feasibility of Florbetapir Quantitation

Avid Pharmaceuticals

Status and phase: Completed; Phase 4

Conditions: Alzheimers Disease

Treatments: Drug: Florbetapir F18

Study type: Interventional

Funder types: Industry

Identifiers

NCT01946243

18F-AV-45-QP01

Details and patient eligibility

About

The overall objective of the study is to assess the feasibility of implementing a quantitative process of florbetapir F 18 scan interpretation. The hypothesis is that the use of quantitative analysis will increase the accuracy of florbetapir F 18 scan interpretation.

Enrollment: 96 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Readers have undergone Amyvid reader training
• Readers have minimal experience with quantitation of amyloid PET scans

Exclusion criteria

• Readers have previously been trained to quantitate amyloid PET scans

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Single Blind

---

96 participants in 1 patient group

Physician Readers

Experimental group

Description:

Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.

Treatment:

Drug: Florbetapir F18